Axys Pharmaceuticals has developed a broad pipeline of small molecule drugs to treat significant diseases, including asthma, blood clotting disorders, arthritis, osteoporosis, cancer, and inflammatory and infectious diseases. Many of Axys' drug programs are in collaboration with leading, global pharmaceutical companies, who provide funding in support of the Axys drug discovery effort.

Axys has the ability to focus on identifying targets at the genetic level of a disease, determine how the disease develops, and use the latest tools and techniques to create the most effective lead compound to interfere with the disease pathway at its most appropriate point. Axys has developed a unique and comprehensive platform of technologies to accomplish this pioneering, gene-to-drug capability. While some of Axys' partners provide clinical development capabilities, Axys has also created an in-house clinical development group to advance Axys' proprietary programs and collaborative programs into clinical testing.

For a comprehensive look at the Axys pipeline, please see the Drug Development Pipeline chart. To take a closer look at Axys' focus on protease inhibitors, please check out Focus on Proteases - or take the Protease Tour.